anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study 1 will use a novel Game Show task, in which the investigators manipulate participant's agency to control their learning environment to specify unguided exploration. In the encoding session, participants play the producer for a game show. On each trial, participants are shown a trial-unique contestant (2s), and then they select one of 3 presented doors to reveal a hidden object (4 seconds). The selected door is then highlighted (2-4s), which is then removed to show a trial-unique object image, which is framed as a prize (2s). On exploration trials, participants actively select which door to open. On control trials, the participant is forced to select a highlighted door, fostering passive rather than active information seeking. Unbeknownst to participants, there is no relationship between selected doors and revealed objects, as objects are pre-selected for each trial. Thus, timing, motor demands, and visual information are fixed across conditions. Participants will complete 3 runs of both the exploration and control condition, with each run containing 20 trials. Temporal jitters are placed between cues and outcomes and between trials, as determined by design optimization software77. Run will be pseudo-randomized across participants so no more than 2 runs of the same condition will appear in a row. Following encoding, participants will complete immediate and delayed item-associative memory test. On each trial of the memory test, participants will view the characters presented during exploration and control trials as well as new foil characters. If a participant indicates that they have previously seen a character before, the participants will be shown three object images encountered during encoding, and decide which item served as a prize for that specific character. In this way, the investigators can resolve memory for contestants (i.e., cues), and associative binding across contestants and prizes (i.e., cue-outcome). Participants memory will be tested for half the stimuli immediately and at a 24-hour delay.
Patients will receive an IV injection of approximately 5 MBq/kg body weight of 18F-FDG (Fludeoxyglucose) (up to 550 MBq). Following injection, patients will undergo CT and PET scans. Intraoperatively, a hand held gamma counter will be used to identify "hot" lymph nodes.
The vacuolar H+-ATPase (V-ATPase) is a functionally conserved multimeric complex localized at the membranes of many organelles where its proton-pumping action is required for proper lumen acidification. The V-ATPase complex is composed of several subunits, some of which have been linked to human disease. We and others previously reported pathogenic dominantly acting variants in ATP6V1B2, the gene encoding the V1B2 subunit, as underlying a clinically variable phenotypic spectrum including dominant deafness-onychodystrophy (DDOD) syndrome, Zimmermann-Laband syndrome (ZLS), and deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures (DOORS) syndrome. Here, we report on an individual with features fitting DOORS syndrome caused by dysregulated ATP6V1C1 function, expand the clinical features associated with ATP6V1B2 pathogenic variants, and provide evidence that these ATP6V1C1/ATP6V1B2 amino acid substitutions result in a gain-of-function mechanism upregulating V-ATPase function that drives increased lysosomal acidification. We demonstrate a disruptive effect of these ATP6V1B2/ATP6V1C1 variants on lysosomal morphology, localization, and function, resulting in a defective autophagic flux and accumulation of lysosomal substrates. We also show that the upregulated V-ATPase function affects cilium biogenesis, further documenting pleiotropy. This work identifies ATP6V1C1 as a new gene associated with a neurodevelopmental phenotype resembling DOORS syndrome, documents the occurrence of a phenotypic continuum between ZLS, and DDOD and DOORS syndromes, and classify these conditions as lysosomal disorders.
Colonoscopy is considered the gold standard for detecting precancerous lesions in the bowel - providing both diagnostic and therapeutic value. Colonoscopy is, ultimately, operator dependent and relies on adequate visualization of these lesions. A multitude of studies have been done to determine the best way to achieve luminal distention that provides the best visualization to detect and remove adenomas. Recent literature has studied the effect of position changes in colonoscopy. Position changes have been theorized to increase luminal distention in the bowel - improving visualization and maneuverability through the colon. Both air and water are used during colonoscopy, with air rising in a dependent fashion in the colon to the highest point. The standard position to perform colonoscopy is left lateral decubitus. In this position, parts of the bowel collapse as air rises into other parts of the bowel. This includes the sigmoid colon and the cecum, both of which are not fixed and can therefore collapse becoming technically challenging to maneuver around. In the right lateral decubitus position, the air rises into these unfixed areas of bowel and are easier to maneuver. A trial by Vergis et al found that right lateral decubitus resulted in quicker examination times and more comfort in their cohort of patients as opposed to the left lateral decubitus position. The investigators note, however, that the population in which this study took place are not comparable to the patients in Newfoundland and in Canada. The investigators also note a study by Ou et al that found position changes had no effect in adenoma detection. Furthermore, a study by Ball et al found conflicting results with position change increased adenoma detection in the right but not the left side of the colon. Conflicting results between all these trials and the populations used have lead to us question if position changes, a cost free and technically easy intervention, can increase visualization in colonoscopy. The investigators propose a randomized controlled trial that compares positioning patients in the right lateral decubitus or left lateral decubitus to aid in luminal distention and visualization, decreasing cecal intubation time and ultimately increasing adenoma detection rate in colonoscopy.

In this trial, participation in the study will be offered when patients present for their scheduled colonoscopy. The patients will be consented at this time for both the colonoscopy procedure and participation in the trial. Patients who consent to take part will then be randomly assigned to either the right or left lateral decubitus starting position. The colonoscopy will then be done in the usual manner with appropriate sedation. Timing throughout the colonoscopy, the number of polyps found and quality of the visualization will then be recorded during the procedure. Patients will then be debriefed regarding their colonoscopy following the procedure in recovery.
Washington University and Dana Farber only: Patients enrolled to this cohort will not receive epacadostat. Patients will undergo standard of care preoperative therapy consisting of approximately 20 to 24 weeks of chemoradiation. All treatment will be administered in this cohort as per institutional standard. The expected schedule for these patients will consist of 1 week of short-course pelvic radiation therapy, followed by a treatment break, followed by neoadjuvant chemotherapy. Approximately 4 to 6 weeks after completion of neoadjuvant chemotherapy, patients may undergo surgery. Tumor biopsy may occur at screening and after completion of RT, prior to starting neoadjuvant chemotherapy.
In December 2019, an outbreak of pneumonia caused by a new coronavirus occurred in Wuhan and spread rapidly throughout China, with the evolution towards a global pandemic. Originally called new coronavirus 2019 (2019-nCoV), the virus was later officially named Coronavirus 2 of Severe Acute Respiratory Syndrome (SARS-CoV-2) by WHO. On 30 January 2020, WHO declared the SARS-CoV-2 outbreak as a public health emergency of international concern. Compared to SARS-CoV, which caused an outbreak of SARS in 2003, SARS-CoV-2 has a higher transmission capacity. Although the clinical manifestations of SARS-CoV-2 are dominated by respiratory symptoms, some patients have severe cardiovascular damage. In addition, patients with underlying cardiovascular disease may be at increased risk of death. Therefore, understanding the impairments caused by SARS-CoV-2 to the cardiovascular system and the underlying mechanisms is of the utmost importance. During this Chinese epidemic, a coagulopathy was found in severe cases of SARS-CoV-2 infection, including significantly higher levels of D-dimers in severe forms, disturbed PT and aPTT ratio compared to survivors (P \<0.05). 71.4% of non-survivors and 0.6% of survivors met the criteria for disseminated intravascular clotting during their hospital stay. This study was confirmed in a second Chinese population where DDimers are still correlated with mortality. The hypothesis of microthrombosis at the renal level was also associated with activation of coagulation since high levels of creatinine were associated with higher levels of DDimers, in favor of a thrombotic origin for kidney failure. Endothelial dysfunction may thus have a major role in the respiratory physiopathologic process as well as in the viral dissemination processes. Indeed, the SARS-CoV-2 receptor (ACE2) is strongly expressed in endothelial cells. Infection of endothelial cells could cause a lesion of the endothelium but also an activation that can trigger the activation of coagulation. Circulating endothelial cells (CECs) are generally considered markers of lesions and may be non-invasive markers of pulmonary vascular dysfunction during SARS-CoV-2 infection. Another marker of endothelial activation could be circulating extracellular vesicles. They could also be involved in the spread of the virus. Thus this project proposes to study different aspects of the diagnosis and pathophysiology of SARS-CoV-2. We propose to fully study activation state of coagulation and endothelium on a plasma and cellular side in patients diagnosed with SARS-CoV-2/COVID19. The different forms of the disease will be included: without lung disease, with a more or less severe lung disease, i.e. having evolved or not towards acute respiratory distress syndrome (ARDS). Extensive research of biomarkers will be compared to the detection of the virus in the respiratory tract as well as in the blood. This work will contribute to a better description of disease pathophysiology and should allow us to identify a patient profile in whom preventive or curative anticoagulant therapy could be considered.
PURPOSE OF THE REVIEW: Despite advances in surgical procedures, cancer recurrence still affects a substantial proportion of patients for whom surgery is considered a curative therapy. This review aims to provide a comprehensive overview of RIOT, addressing its definition, influencing factors, and clinical implications.
FINDINGS: RIOT can be defined as a continuous variable as the time from surgery to initiation of adjuvant therapies or categorically as whether patients can successfully receive adjuvant therapies or not. Factors influencing RIOT are age, sex, socioeconomic status, access to healthcare, physical performance and comorbidities, and quality of anesthesia and surgical care. Adjuvant therapies such as chemotherapy, radiotherapy, and immunotherapy are often administered to reduce the risk of recurrence after surgery and improve survival. Return to intended oncologic therapy (RIOT) has emerged as a promising outcome metric reflecting patients' functional recovery after surgery and their ability to receive adjuvant therapies.
In women with diabetes, hyperglycemia is associated with increased rates of maternal and fetal adverse outcomes. Mothers are at increased risk of preeclampsia, deterioration of proteinuria and caesarean sections. Infants of mothers with diabetes have increased rates of congenital anomalies, premature delivery, macrosomia, stillbirth and NICU admissions, as well as increased risks of shoulder dystocia, birth injury, hypoglycemia, hyperbilirubinemia, respiratory distress syndrome, asphyxia and death in the neonatal period. Several studies have shown that pregnancy outcomes can be improved along with better glycemic control. Theoretically CSII could achieve better glycemic control due to its flexibility in adjusting both basal rate and bolus insulin infusion. Several randomized controlled studies have compared the ability of CSII with multiple daily injection (MDI) in glycemic control and improvement of pregnancy outcomes in patients with type 1 diabetes (T1D). However, there is a lack of similar studies in women with T2D. We hypothesize that CSII will assist women with T2D achieve better glycemic control during pregnancy compared to MDI users.
A technique is provided for servicing a plurality of medical diagnostic systems remotely. The systems are coupled to an internal network of a medical institution or facility. A data communications control system serves to link the institution to a remote service provider via an external network. Service requests and data are generated at the systems or at the control system. The requests are then transmitted to the remote service provider via the control system, and responses to the requests are received by the control system for distribution to the diagnostic systems. The technique permits systems to be remotely serviced which may not be equipped for separate communication via external networks, reduces infrastructure and costs, and facilitates the coordination of service needs of the institution.
The invention relates to a slow-releasing agent or rslow-releasing implanting agent containing antibiotics. The injection comprises slow-releasing micro-sphere and dissolvent. The slow-releasing micro-sphere contains slow-releasing findings and antibiotics, and dissolvent contains suspending adjuvant agent such as sodium carboxymethyl cellulose with the adhesive degree being 100cp-3000cp (at 20-30 Deg. C). The slow-releasing findings comprises EVAc, polyphenyl, PLA, PLGA, decanedioic acid copolymer, albumen glue and gelatin; the slow-releasing implanting agent is prepared with slow-releasing micro-sphere or through other methods. When said antibiotics is placed or injected into bacteria, the medicine can be released slowly for more than 10 days, and toxicity is dramatically reduced at the same time when effective medicine concentration is got and maintained. The said slow-releasing agent is specially effective for chronic medullitis, bedsore, intractable ulcer on skin, diabetes femoral head necrosis and other abscessus, which are caused by Staphylococcus, Streptococcus, Streptococcus, acne Propionibacteriaceae, Enterobacter, Enterobacter, gonotoxin or parameningococcus.
BACKGROUND: The aim of this study was to investigate the clinical features of Nocardia infections, antibiotic resistance profile, choice of antibiotics and treatment outcome, among others. In addition, the study compared the clinical and microbiological characteristics of nocardiosis in bronchiectasis patients and non-bronchiectasis patients.
METHODS: Detailed clinical data were collected from the medical records of 71 non-duplicate nocardiosis patients from 2017 to 2023 at a tertiary hospital in Zhengzhou, China. Nocardia isolates were identified to the species level using MALDI-TOF MS and 16S rRNA PCR sequencing. Clinical data were collected from medical records, and drug susceptibility was determined using the broth microdilution method.
RESULTS: Of the 71 cases of nocardiosis, 70 (98.6%) were diagnosed as pulmonary infections with common underlying diseases including bronchiectasis, tuberculosis, diabetes mellitus and chronic obstructive pulmonary disease (COPD). Thirteen different strains were found in 71 isolates, the most common of which were N. farcinica (26.8%) and N. cyriacigeorgica (18.3%). All Nocardia strains were 100% susceptible to both TMP-SMX and linezolid, and different Nocardia species showed different patterns of drug susceptibility in vitro. Pulmonary nocardiosis is prone to comorbidities such as bronchiectasis, diabetes mellitus, COPD, etc., and Nocardia is also frequently accompanied by co-infection of the body with pathogens such as Mycobacterium and Aspergillus spp. Sixty-one patients underwent a detailed treatment regimen, of whom 32 (52.5%) received single or multi-drug therapy based on TMP-SMX. Bronchiectasis was associated with a higher frequency of Nocardia infections, and there were significant differences between the bronchiectasis and non-bronchiectasis groups in terms of age distribution, clinical characteristics, identification of Nocardia species, and antibiotic susceptibility (P < 0.05).
CONCLUSIONS: Our study contributes to the understanding of the species diversity of Nocardia isolates in Henan, China, and the clinical characteristics of patients with pulmonary nocardiosis infections. Clinical and microbiologic differences between patients with and without bronchiectasis. These findings will contribute to the early diagnosis and treatment of patients.
PURPOSE: A composition for skin external application containing bacteria fermentation extract of sap of bamboo is provided to have skin whitening, anti-aging and skin-moisturizing effects. CONSTITUTION: A composition for skin external application contains bacteria fermentation extract of sap of bamboo as an active ingredient. 0.001-30 wt% of the bacteria fermentation extract of sap of bamboo is contained based on the total weight of the composition. The bacteria is yeast, mushroom bacteria, lactobacillus, koji mould or Bacillus genus. The yeast is Saccharomyces sp., Schizosaccharomyces sp., Torulopsis sp., Rhodotorula sp. or Candida sp. The mushroom bacteria is inonnotus-obliquus, Cordyceps sinensis, Paecilomyces japonica, Tricholomamatsutake, Phellinus linteus or Ganoderma lucidum. The lactobacillus is Lactobacillus sp., Streptococcus sp., Leuconostoc sp. or Bifidobacteria sp.
Water-insoluble drugs are rendered injectable by formulation as aqueous suspensions of phospholipid-coated microcrystals. The crystalline drug is reduced to 50 nm to 10 μm dimensions by sonication or other processes inducing high shear in the presence of phospholipid or other membrane-forming amphipathic lipid. The membrane-forming lipid stabilizes the microcrystal by both hydrophobic and hydrophilic interactions, coating and enveloping it and thus protecting it from coalescence, and rendering the drug substance in solid form less irritating to tissue. Additional protection against coalescence is obtained by a secondary coating by additional membrane-forming lipid in vesicular form associated with and surrounding but not enveloping the lipid-encapsulated drug particles. Tissue-compatible formulations containing drug in concentrations up to 40% (w/v) are described. The preparations can be injected intra-lesionally and in numerous other sites, including intra-venous, intra-arterial, intra-muscular, intra-dermal, etc. The disclosure describes examples of formulations and pharmacokinetic data with antibiotics, anthelmintic drugs, anti-inflammatory drugs, local and general anesthetics, and biologicals.
Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
According to one embodiment of the present invention, provided is a method for managing personal medical information data, which comprises the following steps. A personal medical information management module receives patient information data from a first client. The personal medical information management module generates single key data and stores the data by matching with the patient information data. The personal medical information management module receives the medical information data from the first client. The personal medical information management module performs anonymity of personal information included in the medical information data. The personal medical information management module searches for and matches the single key data of a patient corresponding to the personal information. The personal medical information management module transmits the single key data and the medical information data to a personal medical information analysis/storage module.
Provided are a formulation for a submucosal injection and the use thereof. The formulation comprises a divalent cation and an oligosaccharide. The oligosaccharide is obtained by exposing a polysaccharide powder to radiation, thermal energy, ultrasonic waves, or ultraviolet light. The formulation may be provided as a single solution; or the divalent cation and the oligosaccharide can be packaged separately, wherein the divalent cation is provided in a solution form, and the oligosaccharide is provided in a powder form. The divalent cation may be 0.1-0.5 % w/v of calcium, magnesium, iron, copper, barium, zinc divalent ions, or any combination thereof. The oligosaccharide may be 0.5-2% w/v of degraded sodium alginate, degraded xanthan gum, degraded polydextrose, degraded welan gum, degraded gellan gum, and degraded kelco-crete or mixtures thereof. When the divalent cation comes into contact with the oligosaccharide, the viscosity of the formulation is 1000 cP or more, and the injection pressure of the formulation falls within the range of 2.5-4 kgf.
A method, a computer system, and a computer program product for two-way document generation for medical communication are provided. Patient data from a patient may be received. Medical services provider data from a medical services provider may be received. The patient data and the medical services provider data may be run through a machine learning model so that the machine learning model may produce a first document and a second document. The first document may be presented to the patient. The second document may be presented to the medical services provider.
The present invention provides a compound having an Nrf2 activating effect. Which is a compound represented by the general formula (I), a salt thereof, or a solvate of either: [ in the formula: r 1a And R 1b The same or different, represent a hydrogen atom, an alkyl group or a halogen atom. R 2 Represents a group derived from a heterocyclic ring which may be substituted, and the heterocyclic ring represents thiophene, furan, pyrrole, or thiazole, or a condensed ring containing any of these. R 4 And R 5 The same or different, represent a hydrogen atom or an alkyl group which may be substituted, or R 4 And R 5 Combine with each other to form-NH-CH ═ N-. R 6 Represents an alkyl group which may be substituted. A. the 1 、A 2 、A 3 And A 4 The same or different, represents CH or N (except that N is 1 or less). Z represents a hydrogen atom or a halogen atom.]。